Training in Cancer Therapeutics Research

癌症治疗研究培训

• 批准号: 9331498
• 负责人: EDWARD CHU
• 金额: $ 28.94万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-25 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9331498
• 关键词: Malignant Neoplasms; Therapeutic Human Experimentation; Training

 DESCRIPTION (provided by applicant): Over the past 25-30 years, tremendous advances have been made in our fundamental understanding of the molecular genetics and biology that underlie the development of human cancer. This enhanced understanding of the critical hallmarks of cancer has led to an accelerated development of novel agents and treatment regimens to treat individual cancers, and an increasing number of new drugs are now being approved by the US Food and Drug Administration each year. However, despite these significant advances, there remain significant challenges to the ultimate clinical efficacy of thes new therapies whether they be cytotoxic chemotherapy, targeted therapy, and/or immunotherapy. In general, once advanced disease is diagnosed, the patient is incurable. As a result, there remains an urgent and critical need to train individuals with specific expertise in cancer therapeutics. It is especially important to train individuals with a solid understanding of basic science concepts who can then more effectively and successfully translate basic laboratory findings to the clinical setting as well as incorporate correlative science in clinical trials, which can subsequently inform the basic science. Unfortunately, there remains an insufficient level of interaction between basic scientists and translational/clinical investigators in large part because the two worlds are so different in their scope and priority. As such, we believe that the training of physician-scientists in both pre-clinical and clinical/translational science will greatly advance the field of cancer therapeutics with the eventual goal of developing novel agents and treatment regimens that can make a real difference in the lives of cancer patients. The successful treatment of human cancer requires an integrated multi- and inter-disciplinary approach. The University of Pittsburgh Cancer Institute (UPCI) and the Division of Hematology-Oncology are deeply committed to developing novel cancer therapeutics that span the entire range of classic cytotoxic chemotherapy agents, targeted therapies, immunologic agents, and biologic agents. This Training Program has brought together an outstanding group of investigators from the Division of Hematology-Oncology and from six other departments of the University of Pittsburgh School of Medicine, and the scientific expertise of the training faculy includes the entire continuum of pre-clinical, translational, and clinical cancer therapeutics research. This group of scientists understands the significance of training physician-scientists and proposes to achieve this goal by accomplishing the following aims: (1) Recruit highly promising medical oncology fellows, who are committed to a career in academic medical oncology relevant to the field of cancer therapeutics (2) Provide specific graduate-level course work to enhance their knowledge in molecular and cell biology, immunology, biochemistry, pharmacology, genetics, and clinical/translational medicine (3) Provide an in-depth exposure to basic research skills by working with well-established mentors who are focused on cancer therapeutics. This proposal is for a Training Program for medical oncology fellows that encompasses the entire range of cancer therapeutics research and includes basic, translational, and clinical science. Three medical oncology fellows will be supported for each year of the Program. This Training Program will focus on 5 defined research areas: (1) Cytotoxic Chemotherapy; (2) Targeted Molecular Therapy; (3) Immunotherapy; (4) Investigating Mechanisms of Chemosensitivity and Resistance; and (5) Clinical Investigations. Each of these research areas is well-represented by the members of our training faculty, and a representative of each research area is on the Executive Committee. The training experience will consist of formal course work, seminars, journal clubs, basic laboratory research, and clinical/translational research. Basic laboratory and translational research will form the bulk of the training experience. Each of the trainees will participate in graduate-level courses on the principles and techniques of cancer drug development, cancer biology, signaling, immunology, biochemistry, cell biology, genetics, and clinical trials, as well as courses on the responsible conduct of research each year, which will provide them with the necessary foundation to develop an academic career focused on cancer therapeutics. The trainees will enter a mentor's laboratory for two years, with an optional third year of training if approved by the Executive Committee. Assessment and evaluation will take place every 4 months and this evaluation will be presented to the Executive Committee. Following the Committee meeting, the trainee meets with the Program Director, at which time, the trainee will be asked to evaluate his/her experience in the mentor's laboratory. A two-page written summary by each trainee evaluating their overall training experience is required at the conclusion of the research fellowship. We anticipate that this feedback from faculty and trainees, respectively, will enhance the overall academic productivity of the program.

 描述（由适用提供）：在过去的25 - 30年中，我们对人类癌症发展的基础的基本了解，在我们对分子遗传学和生物学的基本理解中取得了巨大进步。对癌症关键标志的这种增强的理解导致了新型药物和治疗方案的加速发展，以治疗个别癌症，并且每年美国食品药品监督管理局现在都在批准越来越多的新药。但是，尽管取得了重大进展，但无论是细胞毒性化疗，靶向疗法和/或免疫疗法，这些新疗法的最终临床效率仍然存在重大挑战。通常，一旦诊断出晚期疾病，患者就无法治愈。结果，对于培训具有特定专业知识的个人在癌症疗法方面的迫切需求。对个人对基础科学概念有牢固理解的培训尤其重要，他们可以更有效，成功地将基本实验室发现转化为临床环境，并将相关科学纳入临床试验中，这可以随后为基础科学提供信息。不幸的是，基础科学家与翻译/临床研究人员之间的相互作用不足，因为这两个世界的范围和优先级是如此之不同。因此，我们认为，在临床前和临床/转化科学中对身体科学家的培训将大大推动癌症治疗领域，最终的目标是开发新型药物和治疗方案，从而对癌症患者的生活产生真正的影响。人类癌症的成功治疗需要综合的多学科方法。匹兹堡大学癌症研究所（UPCI）和血液肿瘤学的分裂深深地致力于开发新型的癌症治疗，这些癌症疗法遍及整个经典的细胞毒性化学疗法，靶向疗法，免疫学剂和生物学剂。该培训计划汇集了来自血液肿瘤学系和匹兹堡大学医学院其他六个系的杰出研究人员，培训的科学专业知识包括整个前临床，翻译和临床癌症治疗研究的连续性。 This group of scientists understand the significance of training physical-scientists and proposals to achieve this goal by completing the following aims: (1) Recruit highly promise medical oncology fellows, who are committed to a career in academic medical oncology relevant to the field of cancer therapy (2) Provide specific graduate-level course work to enhance their knowledge in molecular and cell biology, immunology, biochemistry, pharmacology, genetics, and clinical/translational医学（3）通过与专注于癌症治疗的知名导师合作，为基础研究技能提供了深入的接触。该建议是针对涵盖整个癌症治疗研究范围的医学肿瘤学研究员的培训计划，其中包括基本，翻译和临床科学。该计划的每一年将支持三名医学肿瘤学研究员。该培训计划将重点关注5个定义的研究领域：（1）细胞毒性化疗； （2）靶向分子疗法； （3）免疫疗法； （4）研究化学敏感性和抗性的机制； （5）临床研究。这些研究领域的每个领域都由我们的培训学院成员很好地代表，每个研究领域的代表都在执行委员会上。培训经验将包括正式的课程工作，半手，期刊俱乐部，基本实验室研究以及临床/翻译研究。基础实验室和翻译研究将构成大部分培训经验。每种培训都将参加有关癌症药物开发，癌症生物学，信号，免疫学，生物化学，生物学，生物学，遗传学和临床试验的原理和技术的研究生课程，以及每年负责任的研究的课程，这将为他们提供对学术培养职业的必要基础。学员将发表两年的心态，如果获得执行委员会的批准，则进行了第三年的可选培训。评估和评估将每4个月进行一次，该评估将提交给执行委员会。委员会会议结束后，学员与计划主任会面，此时，将要求学员评估其在心理实验室中的经历。在研究奖学金结束时，需要每个学员评估其整体培训经验的两页摘要。我们预计，教师和学员的反馈将增强该计划的整体学术产品。